Inflammatory Bowel Disease Treatment Market Research Report – Forecast to 2027

Inflammatory Bowel Disease Treatment Market: Information by Drug Class (TNF Inhibitors, Aminosalicylates) Disease Indication (Ulcerative Colitis, Crohn’s Disease) Distribution Channel (Hospital Pharmacy), End-User (Hospitals & Clinics)—Forecast till 2027

ID: MRFR/Pharma/4805-HCR | | Region: Global | 100 pages

Inflammatory Bowel Disease Treatment Market Scenario


The inflammatory bowel disease treatment market is expected to register a CAGR of 2.5% during the forecast period. Inflammatory bowel disease is characterized by chronic inflammation of the digestive tract. It is an umbrella term for ulcerative colitis and Crohn’s disease. The market for inflammatory bowel disease treatment is growing worldwide due to factors such as the increasing prevalence of ulcerative colitis and Crohn’s disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, increasing number of drugs in clinical trial and growing popularity of prebiotic and probiotic foods is likely to spur market growth. However, high capital investments required for drug discovery, unsatisfactory effectiveness of treatment, and stringent drug regulatory policies are restraining the growth of the inflammatory bowel disease treatment market.


Market Segmentation                                                                                                                         


The inflammatory bowel disease treatment market has been segmented on the basis of drug class, disease indication, distribution channel, and end-user. Based on drug class, the market has been segmented into TNF inhibitors, aminosalicylates, immunomodulators, and corticosteroids.


By disease indication, the market has been segmented into ulcerative colitis and Crohn’s disease.


Based on distribution channel, the market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy.


By end-user, the market has been segmented into hospitals and clinics and others.


Based on region, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has been further segmented into North America and South America. The European market has been further divided into Western Europe and Eastern Europe.


Regional Market Summary


Americas is expected to be the largest inflammatory bowel disease treatment market, by region. The increasing prevalence of anxiety and gluten allergies and inclination towards junk food has led to the increasing number of patients suffering from inflammatory bowel disease in the region. According to the Anxiety and Depression Association of America, anxiety was the most diagnosed mental disorder in the US, with around 40 million people, aged over 14, affected by anxiety every year. As per the Centers for Disease Control and Prevention (CDC), about 1.3% of US adults, approximately 3 million, were diagnosed with IBD, either Crohn’s disease or ulcerative colitis, in 2015. Furthermore, rising health awareness, the presence of key players, and established healthcare infrastructure are likely to enhance the growth of the inflammatory bowel disease treatment market in the region. According to the Centers for Medicare and Medicaid Services (CMS) in 2016, healthcare spending in the US increased by 4.3% to reach USD 3.3 trillion. Thus, increasing per capita income and rising healthcare spending will aid market growth in the Americas.


Europe was the second-largest inflammatory bowel disease treatment market, by region in 2017. The European market is expected to exhibit steady growth during the forecast period owing to the increasing prevalence of inflammatory bowel disease, rising rate of alcohol abuse, unhealthy lifestyle habits, and the increasing incidence of anxiety and depression among adults. Additionally, factors such as increasing government initiatives and funding for research, the development of advanced medical treatment options, and availability of favorable reimbursement policies are likely to propel the growth of the inflammatory bowel disease treatment market in Europe.


Asia-Pacific is expected to be the fastest-growing inflammatory bowel disease treatment market with an exponential rise in patient population. Japan and China are expected to be the largest markets for inflammatory bowel disease treatment in Asia-Pacific. The rising prevalence of anxiety and depression among adults as well as the increasing abuse of alcohol and sedentary lifestyles are expected to result in a growing patient pool, fueling the demand for treatment drugs. Furthermore, comparatively lenient drug regulatory policies and increasing government initiatives for healthcare reform are expected to propel market growth during the forecast period. Rising healthcare expenditure and rising standards of living in the region are also driving the growth of the inflammatory bowel disease treatment market in Asia-Pacific.


The market in the Middle East & Africa is expected to show the least growth due to a lack of awareness about the disease, limited access to and availability of treatment facilities, and lower prevalence of the disorder. However, the market may grow in the UAE, Kuwait, and Saudi Arabia.


Market Players



  • Abbott Laboratories

  • Valeant Pharmaceuticals International

  • Novartis AG

  • Janssen Biotech, Inc.

  • Alkem Laboratories Limited

  • AbbVie, Inc.

  • UCB Inc

  • Takeda Pharmaceutical Company Limited

  • Biogen Inc.

  • Pfizer Inc.

  • Allergan plc


Inflammatory Bowel Disease Treatment Market Share, by Region, 2017 (%)


 Inflammatory Bowel Disease Treatment Market Share


Source: World Health Organization, Centers for Disease Control and Prevention, Expert Interviews, Annual Reports, White Papers, Company Presentations, and Market Research Future Analysis


Market Segmentation and Key players


Inflammatory Bowel Disease Treatment Market, by Drug Class



  • TNF Inhibitors

  • Aminosalicylates

  • Immunomodulators

  • Corticosteroids


Inflammatory Bowel Disease Treatment Market, by Disease Indication



  • Ulcerative Colitis

  • Crohn’s Disease


Inflammatory Bowel Disease Treatment Market, by Distribution Channel



  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy


Inflammatory Bowel Disease Treatment Market, by End-User



  • Hospitals and Clinics

  • Others


Inflammatory Bowel Disease Treatment Market, by Region


North America



  • US

  • Canada


South America


Europe



  • Western Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific


Middle East & Africa



  • UAE

  • Saudi Arabia

  • Oman

  • Kuwait

  • Qatar

  • Rest of the Middle East & Africa


Intended Audience



  • Pharmaceutical manufacturers and suppliers

  • Medical research laboratories

  • Research and development companies

  • Market research and consulting service providers

  • Potential investors



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2.5% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Class, Disease Indication, Distribution Channel, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories, Valeant Pharmaceuticals International, Novartis AG, Janssen Biotech Inc., Alkem Laboratories Limited, AbbVie Inc., UCB Inc, Takeda Pharmaceutical Company Limited, Biogen Inc., Pfizer Inc., Allergan plc
  Key Market Opportunities

  • Increasing number of drugs in clinical trial
  • Growing popularity of prebiotic and probiotic foods
  •   Key Market Drivers

  • Increasing prevalence of ulcerative colitis and Crohn’s disease
  • Advances in medical technology
  • Government support for inflammatory bowel disease treatment research
  • The ubiquity of anxiety and depression


  • Frequently Asked Questions (FAQ) :


    The forecasted CAGR would be 2.5% during the forecast period for Inflammatory Bowel Disease Treatment Market.

    Demand for high capital investment, lack of effective treatment, strict drug regulations are some of the key factors holding the Inflammatory Bowel Disease Treatment Market back.

    The segments are ulcerative colitis and Crohn’s disease included in Inflammatory Bowel Disease Treatment Market report.

    End users included are hospitals, clinics, and others for the Inflammatory Bowel Disease Treatment Market report.

    The Inflammatory Bowel Disease Treatment Market would be dominated by the Americas.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Inflammatory Bowel Disease Treatment Market, by Drug Class

    6.1 Introduction

    6.2 TNF Inhibitors

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Aminosalicylates

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4 Immunomodulators

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.5 Corticosteroids

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 7. Global Inflammatory Bowel Disease Treatment Market, by Disease Indication

    7.1 Introduction

    7.2 Ulcerative Colitis

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.3 Crohn’s Disease

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 8. Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel

    8.1 Introduction

    8.2 Hospital Pharmacy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.3 Retail Pharmacy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4 Online Pharmacy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 9. Global Inflammatory Bowel Disease Treatment Market, by End-User

    9.1 Introduction

    9.2 Hospitals & Clinics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    9.3 Others

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 10. Global Inflammatory Bowel Disease Treatment Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12. Company Profiles

    12.1 Abbott Laboratories

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Valeant Pharmaceuticals International

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Novartis AG

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Janssen Biotech, Inc.

    12.4.1 Company Overview

    12.4.2 Product/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Alkem Laboratories Limited

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 AbbVie, Inc.

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 UCB Inc

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Takeda Pharmaceutical Company Limited

    12.8.1 Overview

    12.8.2 Product Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Biogen Inc.

    12.9.1 Overview

    12.9.2 Product Overview

    12.9.3 Financials

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 Pfizer Inc.

    12.10.1 Overview

    12.10.2 Product Overview

    12.10.3 Financials

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 Allergan plc.

    12.11.1 Overview

    12.11.2 Product Overview

    12.11.3 Financials

    12.11.4 Key Developments

    12.11.5 SWOT Analysis

    12.12 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From the CEO’s Viewpoint

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Predictions for the Inflammatory Bowel Disease Treatment Industry

    Chapter 14. Appendix


    LIST OF TABLES

    Table 1 Global Inflammatory Bowel Disease Treatment Market Synopsis, 2020–2027

    Table 2 Global Inflammatory Bowel Disease Treatment Market Estimates and Forecast, 2020–2027 (USD Million)

    Table 3 Global Inflammatory Bowel Disease Treatment Market, by Region, 2020–2027 (USD Million)

    Table 4 Global Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020–2027 (USD Million)

    Table 5 Global Inflammatory Bowel Disease Treatment Market, by Drug Class, 2020–2027 (USD Million)

    Table 6 Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 7 Global Inflammatory Bowel Disease Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 8 North America: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020–2027 (USD

    Million)

    Table 9 North America: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2020–2027 (USD

    Million)

    Table 10 North America: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 11 North America: Inflammatory Bowel Disease Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 12 US: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020–2027 (USD Milion)

    Table 13 US: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2020–2027 (USD Million)

    Table 14 US: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 15 US: Inflammatory Bowel Disease Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 16 Canada: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020–2027 (USD Million)

    Table 17 Canada: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2020–2027 (USD Million)

    Table 18 Canada: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 19 Canada: Inflammatory Bowel Disease Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 20 South America: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020–2027 (USD Million)

    Table 21 South America: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2020–2027 (USD Million)

    Table 22 South America: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 23 South America: Inflammatory Bowel Disease Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 24 Europe: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020–2027 (USD Million)

    Table 25 Europe: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2020–2027 (USD Million)

    Table 25 Europe: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 26 Europe: Inflammatory Bowel Disease Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 27 Western Europe: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020–2027 (USD Million)

    Table 28 Western Europe: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2020–2027 (USD Million)

    Table 29 Western Europe: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 30 Western Europe: Inflammatory Bowel Disease Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 31 Eastern Europe: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020–2027 (USD Million)

    Table 32 Eastern Europe: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2020–2027 (USD Million)

    Table 33 Eastern Europe: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 34 Eastern Europe: Inflammatory Bowel Disease Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 35 Asia-Pacific: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020–2027 (USD Million)

    Table 36 Asia-Pacific: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2020–2027 (USD Million)

    Table 37 Asia-Pacific: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 38 Asia-Pacific: Inflammatory Bowel Disease Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 39 Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020–2027 (USD Million)

    Table 40 Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2020–2027 (USD Million)

    Table 41 Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 42 Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by End-User, 2020–2027 (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Inflammatory Bowel Disease Treatment Market

    Figure 3 Segmentation Market Dynamics for Inflammatory Bowel Disease Treatment Market

    Figure 4 Global Inflammatory Bowel Disease Treatment Market Share, by Disease Indication, 2020

    Figure 5 Global Inflammatory Bowel Disease Treatment Market Share, by Drug Class, 2020

    Figure 6 Global Inflammatory Bowel Disease Treatment Market Share, by Distribution Channel, 2020

    Figure 7 Global Inflammatory Bowel Disease Treatment Market Share, by End-User, 2020

    Figure 8 Global Inflammatory Bowel Disease Treatment Market Share, by Region, 2020

    Figure 9 North America: Inflammatory Bowel Disease Treatment Market Share, by Country, 2020

    Figure 10 Europe: Inflammatory Bowel Disease Treatment Market Share, by Country, 2020

    Figure 11 Asia-Pacific: Inflammatory Bowel Disease Treatment Market Share, by Country, 2020

    Figure 12 Middle East & Africa: Inflammatory Bowel Disease Treatment Market Share, by Country, 2013

    Figure 13 Global Inflammatory Bowel Disease Treatment Market: Company Share Analysis, 2020 (%)

    Figure 14 Abbott Laboratories: Key Financials

    Figure 15 Abbott Laboratories: Segmental Revenue

    Figure 16 Abbott Laboratories: Geographical Revenue

    Figure 17 Thermo Fisher Scientific. Key Financials

    Figure 18 Novartis AG: Segmental Revenue

    Figure 19 Novartis AG: Geographical Revenue

    Figure 20 Takeda Pharmaceutical Company Limited: Key Financials

    Figure 21 Takeda Pharmaceutical Company Limited: Segmental Revenue

    Figure 22 Takeda Pharmaceutical Company Limited: Geographical Revenue

    Figure 23 Pfizer Inc.: Key Financials

    Figure 24 Pfizer Inc.: Segmental Revenue

    Figure 25 Pfizer Inc.: Geographical Revenue

    Figure 26 Biogen Inc.: Key Financials

    Figure 27 Biogen Inc.: Segmental Revenue

    Figure 28 Biogen Inc.: Geographical Revenue

    Figure 29 Valeant Pharmaceuticals International: Key Financials

    Figure 30 Valeant Pharmaceuticals International: Segmental Revenue

    Figure 31 Valeant Pharmaceuticals International: Geographical Revenue